Palisade Bio (NASDAQ: PALI) delays special meeting to Sept. 26

Rhea-AI Filing Summary

Palisade Bio, Inc. postponed its special meeting of stockholders because there were not enough shares of common stock represented in person or by proxy to reach a quorum. The meeting, originally convened on September 18, 2025, was adjourned and is scheduled to reconvene on September 26, 2025 at 10:00 a.m. Pacific Time.

The close of business on July 28, 2025 remains the record date, so only stockholders of record on that date are entitled to vote at the reconvened meeting. The proposals to be voted on are unchanged, and stockholders who already voted and do not wish to change their vote do not need to take any further action. Voting instructions are provided in the company’s definitive proxy statement on Schedule 14A and through the proxy voting platform.

false 0001357459 0001357459 2025-09-18 2025-09-18 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 18, 2025

PALISADE BIO, INC.

(Exact name of Registrant as Specified in Its Charter)

Delaware		001-33672		52-2007292
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

1902 Wright Place Suite 200
Carlsbad, California		92008
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s telephone number, including area code: (858) 704-4900

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.01 per share		PALI		Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01. Other Events.

On September 18, 2025, Palisade Bio, Inc. (the “Company”) convened and then determined to adjourn, without conducting any business, a special meeting of stockholders (the “Special Meeting”) because the Company did not have a sufficient number of shares of the Company’s Common Stock present in person or represented by proxy at the Special Meeting to constitute a quorum. The adjourned Special Meeting will reconvene on Friday, September 26, 2025 at 10:00 a.m. Pacific Time.

The close of business on July 28, 2025 will continue to be the record date for the determination of stockholders of the Company entitled to vote at the Special Meeting. No changes have been made to the proposals to be voted on by stockholders at the Special Meeting. Stockholders who have previously submitted their proxy or otherwise voted and do not want to change their vote do not need to take any action. Stockholders may cast their votes by following the instructions set forth in the Company’s definitive proxy statement on Schedule 14A which was filed with the Securities and Exchange Commission on August 18, 2025 which is available on the SEC’s website at www.sec.gov, and the voting platform at www.proxydocs.com/PALI.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.

Date: September 18, 2025	Palisade Bio, Inc.
		/s/ J.D. Finley
	By:	J.D. Finley
		Chief Executive Officer

FAQ

What did Palisade Bio (PALI) disclose in this 8-K filing?

Palisade Bio, Inc. disclosed that its special meeting of stockholders was convened on September 18, 2025 but immediately adjourned without conducting any business because a quorum was not present. The company set a new date and time for the meeting to reconvene.

When will Palisade Bio’s adjourned special meeting reconvene?

The adjourned special meeting of Palisade Bio, Inc. is scheduled to reconvene on September 26, 2025 at 10:00 a.m. Pacific Time.

What is the record date for Palisade Bio’s special meeting?

The record date remains the close of business on July 28, 2025. Only stockholders of record on that date are entitled to vote at the reconvened special meeting.

Were any proposals or agenda items changed for the Palisade Bio special meeting?

No. The filing states that no changes have been made to the proposals to be voted on by stockholders at the special meeting.

Do Palisade Bio stockholders need to vote again for the reconvened special meeting?

Stockholders who have already submitted their proxy or otherwise voted and do not want to change their vote do not need to take any action. Their prior votes will remain valid for the reconvened meeting.

How can Palisade Bio stockholders vote or change their vote for the special meeting?

Stockholders may cast or change their votes by following the instructions in Palisade Bio’s definitive proxy statement on Schedule 14A, available on the SEC’s website, and through the voting platform at www.proxydocs.com/PALI.